How we make this list: we compare pricing pages, product documentation and public user reviews. Ratings come from G2, Capterra or Trustpilot, with the date we checked them.
Key takeaways
- Preclinical CRO "reviews" work differently from consumer reviews: the real signals are regulatory inspection history, repeat sponsor relationships, and on-time study delivery.
- Large CROs win on integrated capacity and global sites, while mid-size CROs win on senior attention and flexibility for small biotech teams.
- GLP compliance is non-negotiable for studies that will support an IND, so confirm the specific lab's GLP status, not just the parent company's reputation.
- Bioanalysis and DMPK quality often matter more than headline toxicology capacity, because weak analytical data can delay an entire program.
- Pricing is always project-based in this market, so request itemized proposals from at least three CROs and compare study designs, not just totals.
Quick comparison
Is your product missing or out of date?
We review this list regularly. Vendors can request a listing, send updated pricing or ask about featured placement.
The best preclinical CRO companies
#1
Charles River Laboratories
Best for: Integrated safety assessment at global scale
Visit criver.com
Starting priceSee website
Free planNo
Charles River Laboratories is the largest name in preclinical services, and its reputation rests on breadth: research models, discovery support, safety assessment, and biologics testing under one roof, with sites across the Americas, Europe, and Asia. For sponsors, the practical advantage is integration: the same organization can run discovery pharmacology, GLP toxicology, and bioanalysis without handoffs between vendors, which reduces transfer risk. Its scientific consulting teams also help sponsors design studies that regulators will accept, a service smaller CROs often cannot staff at the same depth.
The trade-offs are scale-related. Charles River is a premium-priced provider, and small biotech teams sometimes find they get less senior attention than at a mid-size CRO. Lead times at popular sites can also stretch, so early engagement matters. For programs that need global capacity, proven GLP infrastructure, and a partner whose data regulators already know well, Charles River remains the default first call.
What we like- Full continuum from research models to safety assessment
- Deep GLP toxicology capacity
- Strong scientific consulting bench
Watch out for- Premium pricing and scale can feel impersonal for tiny programs
- Lead times at busy sites
#2
Labcorp Drug Development
Best for: Preclinical to clinical continuity
Visit labcorp.com
Starting priceSee website
Free planNo
Labcorp Drug Development combines preclinical services with one of the world's largest clinical development organizations and a global diagnostics business. That combination matters when a program moves from animal studies into first-in-human trials: bioanalytical methods, safety data, and central lab processes can carry forward without changing vendors. Its Greenfield, Indiana laboratory expanded molecular testing capabilities in 2024, including assay development and vector analysis for gene and cell therapies, which reflects where preclinical demand is heading.
The downside mirrors Charles River's: a company of this size can be slower to pivot, and preclinical sponsors compete for attention with much larger clinical programs. Pricing is project-based and negotiated. For sponsors planning a long arc from preclinical work through clinical trials, Labcorp's continuity is a genuine advantage worth paying for.
What we like- Smooth handoff from preclinical to clinical phases
- Huge central lab and bioanalysis network
- Strong diagnostics parent
Watch out for- Size can mean slower decision-making
- Preclinical services sit inside a much larger company
Starting priceSee website
Free planNo
WuXi AppTec operates an integrated contract research, development, and manufacturing platform spanning chemistry, biology, testing, and manufacturing, with operations across Asia, Europe, and North America and partners in more than 30 countries. For sponsors, the appeal is a single partner from discovery chemistry through preclinical testing and into manufacturing, under one quality system. The company has earned repeated industry recognition, including a Frost and Sullivan global company of the year award in CRDMO for ten consecutive years.
The caveat is geopolitical. US legislative scrutiny of Chinese-linked biotech vendors has led some American sponsors to hedge by splitting work with European or Indian providers, even while continuing to use WuXi for non-sensitive programs. Sponsors should assess their own risk tolerance and program sensitivity before committing. For integrated programs where cost, capacity, and speed matter most, WuXi remains one of the strongest platforms in the world.
What we like- End-to-end CRDMO platform across Asia, Europe, and North America
- Partners in more than 30 countries
- Repeated industry recognition
Watch out for- Geopolitical scrutiny, including US BIOSECURE Act exposure, prompts some sponsors to hedge
- Complexity of a very large platform
#4
Eurofins Scientific
Best for: Analytical testing depth across 57 countries
Visit eurofins.com
Starting priceSee website
Free planNo
Eurofins Scientific is best known as an analytical testing giant, with more than 950 laboratories in 57 countries, over 65,000 employees, and more than 450 million tests performed per year. Its drug development work covers preclinical through commercialization, with particular strength in pharmacokinetic analysis, immunogenicity testing, and biomarker measurement. Its Viracor BioPharma arm expanded bioanalytical capacity in Lenexa, Kansas in 2026. For sponsors whose bottleneck is analytical quality, such as complex biologics or immunogenicity questions, Eurofins' method depth is hard to match.
Eurofins is less of an end-to-end drug development partner than Charles River or Labcorp: it excels at testing and analysis rather than owning a whole program. Its size also means sponsors should identify the right lab and team rather than treating the brand as a single service. For bioanalysis-heavy programs and device biocompatibility work, Eurofins is a top choice.
What we like- More than 950 laboratories in 57 countries
- Over 200,000 analytical methods
- Strong in bioanalysis and device biocompatibility
Watch out for- Analytical focus means less end-to-end drug development than full-service CROs
- Navigating a huge network takes effort
Starting priceSee website
Free planNo
ICON is one of the largest clinical research organizations in the world, and its early clinical and bioanalytical solutions make it a natural preclinical partner for sponsors heading toward first-in-human studies. Its specialty laboratory services support precision medicine programs across all phases, and its biotech-focused teams offer flexible support including due diligence and asset valuation. Sponsors value the ability to keep bioanalytical methods and early-phase expertise in one organization as programs advance.
The trade-off is that ICON's center of gravity is clinical development, so a purely preclinical sponsor may find more dedicated attention at a preclinical specialist. Pricing is project-based and reflects enterprise scale. For sponsors whose preclinical work is the on-ramp to a clinical program, ICON's continuity and lab depth are compelling.
What we like- Strong early clinical and bioanalytical solutions
- Specialty lab support across all phases
- Large global footprint
Watch out for- Clinical-heavy organization means preclinical work is one part of a bigger machine
- Premium pricing
Starting priceSee website
Free planNo
Frontage Laboratories positions itself as a science-driven partner for drug discovery and development, with services spanning DMPK, safety and toxicology, bioanalytical work, CMC, and clinical trials. With 25 years of growth, 28 sites across North America, Asia Pacific, and Europe, and more than 200 FDA inspections on record, it has earned a reputation among small and mid-size biotech teams for collaborative science and responsive project management. Its DMPK and bioanalysis capabilities are frequently cited as strengths in industry comparisons.
Frontage cannot match the sheer capacity of Charles River or Labcorp at a single site, and sponsors with very large toxicology programs may need a bigger partner. For small biotech teams that want senior scientists on their calls and flexible study design, Frontage is one of the best-regarded mid-size options.
What we like- Strong DMPK, bioanalytical, and safety and toxicology services
- 28 sites across North America, Asia Pacific, and Europe
- 200-plus FDA inspections
Watch out for- Smaller than the top-tier giants, so capacity at a single site is more limited
- Less known for large-scale toxicology
Starting priceSee website
Free planNo
Altasciences is a mid-size early-phase CRO in Canada and the US that moves molecules from preclinical safety testing through Phase I and II clinical pharmacology, bioanalysis, and manufacturing and analytical services. Its published client feedback consistently praises scientific knowledge, efficient and timely processes, and communication from protocol draft to final report, which is exactly what small sponsors say they miss at larger CROs. Its integrated early-phase model suits biotech teams that want one partner from animal studies into first-in-human work without the overhead of a giant.
The limitation is scale: very large or multi-region programs may outgrow Altasciences, and its footprint is narrower than the global giants. For early-phase programs where senior attention, speed, and clear communication matter more than global capacity, Altasciences earns its strong reputation.
What we like- Proven preclinical safety testing plus Phase I to II clinical pharmacology
- Client testimonials praise communication and timeliness
- Canada and US sites
Watch out for- Mid-size scale limits capacity for very large programs
- Smaller global footprint than the giants
#8
Inotiv
Best for: Research models paired with nonclinical services
Visit inotiv.com
Starting priceSee website
Free planNo
Inotiv combines two things most CROs keep separate: the industry's broadest range of research models and a full nonclinical services business covering general toxicology, histology, pathology, DMPK, and clinical bioanalysis. That pairing matters because model quality and consistency directly affect study data, and Inotiv controls both sides. Its digital pathology offering, with whole-slide imaging and AI-driven quantitative analysis, and its mass spectrometry assays for antibody-drug conjugate targets show where its scientific investment is going.
Inotiv's services footprint is smaller than Charles River's or Labcorp's, and some sponsors still think of it primarily as a model supplier. For programs where model selection, welfare standards, and nonclinical data quality are tightly linked, Inotiv is a distinctive and well-regarded choice.
What we like- Broadest range of research models in the industry, paired with toxicology, pathology, and DMPK
- Digital pathology and mass spectrometry assay depth
Watch out for- Research model supply business can overshadow services in perception
- Smaller services footprint than top-tier CROs
How we chose
We selected CROs that appear consistently across independent market analyses of the preclinical CRO sector and that offer genuine preclinical services, not only clinical work. We weighted regulatory track record, service breadth in toxicology, bioanalysis, and DMPK, global or regional capacity, and evidence of sponsor satisfaction such as repeat business and published client feedback. Because B2B CROs do not accumulate consumer star ratings, we did not invent rating scores; instead we described each company's documented strengths and limits. Pricing is project-based across this market, so every starting price is listed as "See website" and sponsors should request itemized proposals.
What to check before you hire
Start with regulatory fit. Confirm that the specific laboratory running your study is GLP-compliant for your study type and that its recent inspection history is clean, and ask for the study director's experience in your therapeutic area. Next, compare study designs, not just prices: a cheaper protocol that regulators reject costs far more than a thorough one. Ask about bioanalytical method validation timelines, since analytical delays are a common bottleneck.
Check capacity and communication. Who is your day-to-day contact, how often will you receive updates, and what happens if a study director leaves mid-program? Confirm data ownership and transfer terms, including raw data formats and timelines for final reports. Finally, run a small pilot or method validation project before committing a full program: how a CRO handles a small engagement predicts how it will handle a large one.
Frequently asked questions
What does a preclinical CRO do?
A preclinical CRO runs the laboratory studies that test a drug candidate's safety and behavior before human trials, including toxicology, pharmacology, bioanalysis, and pharmacokinetics. It designs studies, runs them under good laboratory practice rules, analyzes samples, and delivers reports that support an investigational new drug application.
How much does preclinical CRO work cost?
Costs vary enormously by study type, species, duration, and analytical complexity, from tens of thousands of dollars for a small pharmacokinetic study to millions for a full toxicology program. All pricing is project-based, so request itemized proposals from several CROs and compare the study designs behind each total.
What is GLP and why does it matter?
Good laboratory practice is a quality system governing how nonclinical safety studies are planned, performed, recorded, and reported. Regulators require GLP compliance for studies that support drug approval, so a non-GLP study usually cannot support an IND filing. Always confirm the specific lab's GLP status for your study type.
Should I choose a large CRO or a mid-size one?
Large CROs offer integrated capacity, global sites, and regulatory familiarity, while mid-size CROs often give more senior attention, faster decisions, and greater flexibility. Small biotech teams frequently prefer mid-size partners, while large pharma programs with global timelines usually need large ones. Many sponsors use both: a large CRO for pivotal toxicology and a specialist for bioanalysis.
How do I verify a CRO's reputation?
Ask for references from sponsors in your therapeutic area, check FDA inspection history where available, review published client feedback, and ask about repeat business rates. A site visit or audit of the specific laboratory, rather than the parent company's brand, gives the most reliable picture.
Sources we checked (8)
- https://www.criver.com
- https://www.labcorp.com
- https://www.wuxiapptec.com
- https://www.eurofins.com
- https://www.iconplc.com
- https://www.frontagelab.com
- https://www.altasciences.com
- https://www.inotiv.com
Is your product missing or out of date?
We review this list regularly. Vendors can request a listing, send updated pricing or ask about featured placement.
Shihab Mia · Founder, Rankite
Shihab has 5+ years in B2B and SaaS SEO. He writes Rankite's software buying guides from pricing pages, documentation and public user reviews. More about Shihab.
WuXi AppTec
ICON
Frontage Laboratories
Altasciences